Live Breaking News & Updates on Alar pharmaceuticals inc

Stay informed with the latest breaking news from Alar pharmaceuticals inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Alar pharmaceuticals inc and stay connected to the pulse of your community

Indivior (NASDAQ:INDV) versus Agile Therapeutics (NASDAQ:AGRX) Head to Head Comparison

Agile Therapeutics (NASDAQ:AGRX – Get Free Report) and Indivior (NASDAQ:INDV – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk. Profitability This table compares Agile Therapeutics and Indivior’s net […]

United-states , Virginia , United-kingdom , New-jersey , Aelis-farma , Alar-pharmaceuticals-inc , Agile-therapeutics-inc , Agile-therapeutics , Get-free-report , Given-agile-therapeutic , North-chesterfield , Agile-therapeutics-daily

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

/PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop,...

United-states , Hong-kong , Macau , China , Taiwan , Christian-heidbreder , Alar-pharmaceuticals-inc , Nasdaq , Prnewswire-indivior , Lead-asset , First-three-month , Alar-pharmaceuticals

Indivior (INDV) Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Indivior (INDV) Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong-kong , Taiwan , China , Macau , Christian-heidbreder , Nasdaq , Alar-pharmaceuticals-inc , Alar-pharmaceuticals , Chief-scientific ,

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

China , Macau , Taiwan , Hong-kong , United-states , Christian-heidbreder , Alar-pharmaceuticals-inc , Nasdaq , Prnewswire-indivior , Lead-asset , First-three-month , Alar-pharmaceuticals

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

Macau , Taiwan , Hong-kong , United-states , China , Christian-heidbreder , Alar-pharmaceuticals-inc , Nasdaq , Prnewswire-indivior , Lead-asset , First-three-month , Alar-pharmaceuticals

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

/PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs)...

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc- ,

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting fr...

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc ,

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

/PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs)...

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc- ,

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Taiwan , Prnewswire-alar-pharmaceuticals-inc , Alar-pharmaceuticals-inc , Business , Health , Pr-newswire , Opioids ,

Rompre le cycle de la dépendance aux opioïdes : Alar présente les résultats intermédiaires positifs de la buprénorphine injectable à action prolongée (ALA-1000) chez les patients dépendants aux opioïdes

Rompre le cycle de la dépendance aux opioïdes : Alar présente les résultats intermédiaires positifs de la buprénorphine injectable à action prolongée (ALA-1000) chez les patients dépendants aux opioïdes
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Links-to-related-source-alar-pharmaceuticals , Alar-pharmaceuticals , Alar-pharmaceuticals-inc , Dalar-pharmaceuticals , Yung-shun-wen , American-fda , D-alar-pharmaceuticals , Pharmaceuticals-inc , Following-links